FILED NOT FOR PUBLICATION MAY 19 2020 UNITED STATES COURT OF APPEALS MOLLY C. DWYER, CLERK U.S. COURT OF APPEALS

FOR THE NINTH CIRCUIT

KARIM KHOJA, on behalf of himself and No. 16-56069 all others similarly situated, DC No. 3:15 cv-00540 JLS Plaintiff-Appellant, MEMORANDUM* v. PROVINCE, INC., as the Wind Down Administrator for Orexigen Therapeutics, Inc.; JOSEPH P. HAGAN; MICHAEL A.

NARACHI; PRESTON KLASSEN, Defendants-Appellees.

Appeal from the United States District Court for the Southern District of California Janis L. Sammartino, District Judge, Presiding Argued and Submitted November 6, 2017 Pasadena, California Administratively Closed August 13, 2018 Resubmitted April 28, 2020**

* This disposition is not appropriate for publication and is not precedent except as provided by Ninth Circuit Rule 36-3. ** The panel unanimously concludes this case is suitable for resubmission for decision without oral argument. See Fed. R. App. P. 34(a)(2).

Before: TASHIMA and BERZON, Circuit Judges, and PAYNE,*** District Judge.

On August 13, 2018, we filed our opinion in this case, Khoja v. Orexigen Therapeutics Inc., 899 F.3d 988 (9th Cir. 2018), cert. denied, sub nom. Hagen v. Khoja, 1395 S. Ct. 2615 (2019). Because, during the pendancy of this appeal, Orexigen filed a voluntary Chapter 11 petition, and the automatic stay of 11 U.S.C. § 362(a) came into effect, we noted that that “opinion [did] not address or decide Plaintiff’s appeal as against defendant-appellee Orexigen.” Id. at 994 n.1.

Orexigen’s successor in interest, Province, Inc., as the Wind Down Administrator for Orexigen Therapeutics Inc.,1 has now filed a status report indicating that the bankruptcy court, per the parties’ stiuplation, has lifted the § 362 stay with respect to this case. We have therefore resubmitted this appeal for decision with respect to Orexigen.2

*** The Honorable Robert E. Payne, United States District Judge for the Eastern District of Virginia, sitting by designation.

For convenience, we refer to Orexigen’s successor, the Wind Down Administrator, as “Orexigen.”

We note that Orexigen fully participated in the briefing and oral argument on November 6, 2017; the § 362 stay did not come into effect until after oral argument and submission of the case for decision. See id. We have, again, reviewed the parties’ briefs and our opinion in Orexigen.

After such review, we fully adopt our opinion in Orexigen, 899 F.3d 988, to resolve Plaintiff’s appeal as against Defendant Orexigen.

Therefore, with respect to Plaintiff’s appeal as against Defendant-Appellee Province, Inc., as the Wind Down Administrator for Orexigen Therapeutics, Inc., the judgment of the district court is AFFIRMED in part, REVERSED in part, and REMANDED. No costs.